Skip to content
- TCRT: A $350 Million Biotech Deal Makes Dilution the Essential Question
- SITC: A $3 Cash Distribution Comes With a NYSE Exit—and a Trading Catch
- ATOS: The Potential $50 Million Shareholder Payout Is a Conditional Right
- MWYN: Marwynn’s AI and Digital-Asset Ambitions Face a Revenue Test
- SEED: Fresh Capital and Stress-Tolerant Corn Give Origin Agritech a New Story
- CCEL: Cryo-Cell Earns More Without Growing Sales—Can It Last?
- XELB: Can Jenny Martinez’s Online Audience Become a Grocery Business?
- EVAX: Evaxion Approaches a Cancer-Vaccine Data Test
- SAFX: A Merger and Production Progress Give XCF’s Rebound a Story to Test
- XLAB: An $8.2 Million Nvidia-Server Deal Gives the Rally a Concrete Catalyst
